Advertisement

Needle Biopsy Sampling Techniques and Role of Multiparametric-Magnetic Resonance Imaging Modality in Prostate Cancer Diagnosis and Management

  • Rajal B. ShahEmail author
  • Ming Zhou
Chapter

Abstract

The clinicopathological characteristics of newly diagnosed prostate cancer have significantly changed due to widespread prostate-specific antigen (PSA) screening after its introduction in the late 1980s. The most remarkable change has been “stage migration” toward smaller volume disease at a younger age. The diagnosis of prostate cancer now is mostly triggered by an elevated or rising PSA rather than an abnormal digital rectal examination, resulting in a significant increase in the percentage of nonpalpable cancers (stage T1C) between 1988 and 1996 from 10% to 73%. With this trend, the prostate biopsy application and sampling techniques have also rapidly evolved. In 1989, the transrectal ultrasound (TRUS)-guided sextant prostate biopsy was introduced and rapidly became the standard over directed biopsies of hypoechoic lesions and palpable nodules. In recent years, it has become increasingly evident that sextant biopsies could miss a significant number (up to 30%) of cancers because only a small percentage of prostates has a tumor distribution detectable with the paramedian template utilized by the sextant approach. Furthermore, sextant protocol tends to undersample certain areas of the prostate, such as “anterior horns” and the lateral aspects of the peripheral zone, where majority of prostate cancer arises. Recent studies suggested moving the biopsies more laterally to better sample the lateral aspects and anterior horns of the peripheral zones. This recommendation was supported by the zonal anatomy of the prostate as well as the origin of the tumor. Because approximately 80% of prostate cancers originate in the peripheral zone, extended biopsy templates that more extensively sample this region could improve the cancer detection rate.

The main disadvantage of TRUS-guided prostate biopsy, however, is that it misses a substantial proportion of clinically significant cancers (approximately 20%) because of sampling errors, especially in the anterior part of the prostate gland, and a high proportion of men are diagnosed with clinically insignificant disease, which may result in subsequent overtreatment. Owing to its high soft-tissue contrast, high resolution, and ability to simultaneously image functional parameters, multiparametric-magnetic resonance imaging (mp-MRI) provides the best visualization of the prostate compared to other imaging methods. Over the past years, mp-MRI use has shifted from staging purposes to detection and tumor localization and prediction of clinically significant cancers. This chapter discusses the application of various TRUS and MRI-guided sampling methods and their impact on day-to-day practice.

Keywords

Prostate-specific antigen Nonpalpable cancers (stage T1C) Sextant biopsy Extended biopsy Saturation biopsy Transrectal biopsy Transperineal biopsy Multiparametric-magnetic resonance imaging, mp-MRI T2-weighted imaging, T2W Diffusion-weighted imaging, DWI Apparent diffusion coefficient, ADC Dynamic contrast-enhanced imaging, DCEI Magnetic resonance spectroscopy imaging, MRSI Targeted biopsy Fusion imaging Region of interest, ROI PI-RADS score 

References

  1. 1.
    Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994;151:1283–90.CrossRefGoogle Scholar
  2. 2.
    Chen ME, Troncoso P, Tang K, Babaian RJ, Johnston D. Comparison of prostate biopsy schemes by computer simulation. Urology. 1999;53:951–60.CrossRefGoogle Scholar
  3. 3.
    Stamey TA. Making the most out of six systematic sextant biopsies. Urology. 1995;45:2–12.CrossRefGoogle Scholar
  4. 4.
    Emiliozzi P, Maymone S, Paterno A, Scarpone P, Amini M, Proietti G, et al. Increased accuracy of biopsy Gleason score obtained by extended needle biopsy. J Urol. 2004;172:2224–6.CrossRefGoogle Scholar
  5. 5.
    Herawi M, Kahane H, Cavallo C, Epstein JI. Risk of prostate cancer on first re-biopsy within 1 year following a diagnosis of high grade prostatic intraepithelial neoplasia is related to the number of cores sampled. J Urol. 2006;175:121–4.CrossRefGoogle Scholar
  6. 6.
    Hodge KK, McNeal JE, Terris MK, Stamey TA. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol. 1989;142:71–4; discussion 74–75.CrossRefGoogle Scholar
  7. 7.
    National Comprehensive Cancer Network. NCCN clinical guidelines in oncology: prostate cancer early detection. 2017. Available at: NCCN.org.
  8. 8.
    Norberg M, Egevad L, Holmberg L, Sparén P, Norlén BJ, Busch C. The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. Urology. 1997;50:562–6.CrossRefGoogle Scholar
  9. 9.
    Presti JC Jr, O’Dowd GJ, Miller MC, Mattu R, Veltri RW. Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multi-practice study. J Urol. 2003;169:125–9.CrossRefGoogle Scholar
  10. 10.
    San Francisco IF, DeWolf WC, Rosen S, Upton M, Olumi AF. Extended prostate needle biopsy improves concordance of Gleason grading between prostate needle biopsy and radical prostatectomy. J Urol. 2003;169:136–40.CrossRefGoogle Scholar
  11. 11.
    Schlesinger C, Bostwick DG, Iczkowski KA. High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation: predictive value for cancer in current practice. Am J Surg Pathol. 2005;29:1201–7.CrossRefGoogle Scholar
  12. 12.
    Siu W, Dunn RL, Shah RB, Wei JT. Use of extended pattern technique for initial prostate biopsy. J Urol. 2005;174:505–9.CrossRefGoogle Scholar
  13. 13.
    Watanabe M, Hayashi T, Tsushima T, Irie S, Kaneshige T, Kumon H. Extensive biopsy using a combined transperineal and transrectal approach to improve prostate cancer detection. Int J Urol. 2005;12:959–63.CrossRefGoogle Scholar
  14. 14.
    Emiliozzi P, Corsetti A, Tassi B, Federico G, Martini M, Pansadoro V. Best approach for prostate cancer detection: a prospective study on transperineal versus transrectal six-core prostate biopsy. Urology. 2003;61:961–6.CrossRefGoogle Scholar
  15. 15.
    Gayet M, van der Aa A, Beerlage HP, Schrier BP, Mulders PF, Wijkstra H. The value of magnetic resonance imaging and ultrasonography (MRI/US)-fusion biopsy platforms in prostate cancer detection: a systematic review. BJU Int. 2016;117:392–400.CrossRefGoogle Scholar
  16. 16.
    Johnson LM, Turkbey B, Figg WD, Choyke PL. Multiparametric MRI in prostate cancer management. Nat Rev Clin Oncol. 2014;11:346–53.CrossRefGoogle Scholar
  17. 17.
    Loffroy R, Chevallier O, Moulin M, Favelier S, Genson PY, Pottecher P, et al. Current role of multiparametric magnetic resonance imaging for prostate cancer. Quant Imaging Med Surg. 2015;5:754–64.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Marko J, Gould CF, Bonavia GH, Wolfman DJ. State-of-the-art imaging of prostate cancer. Urol Oncol. 2016;34:134–46.CrossRefGoogle Scholar
  19. 19.
    Purysko AS, Rosenkrantz AB, Barentsz JO, Weinreb JC, Macura KJ. PI-RADS version 2: a pictorial update. Radiographics. 2016;36:1354–72.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Robert J Tomsich Pathology and Laboratory Medicine InstituteCleveland ClinicClevelandUSA
  2. 2.Tufts Medical CenterBostonUSA

Personalised recommendations